Brochures Overview
Antibody-drug conjugates (ADCs) represent emerging biotherapeutics that are composed of cytotoxic payloads conjugated to a monoclonal antibody (mAb) via a chemical linker. Characterization of the ADME properties of ADCs is much more challenging. Based on our experience in ADC project research, we divided the ADC DMPK study into four main aspects: ADME, in vitro DDI, PK/TK and bioanalysis. These four aspects have their own emphasis in the discovery, preclinical and clinical stages. The WuXi AppTec DMPK team will propose a pharmacokinetic study strategy and study method for each ADC project based on their structures to accelerate the development and application of ADCs.
Complete the form to view and download this brochure.
Stay Connected
Keep up with the latest news and insights.